ACADIA Pharmaceuticals Inc. (ACAD) wird mit einem nachlaufenden KGV von gehandelt 9.7, erwartetes KGV von 49.4. Die nachlaufende Gewinnrendite beträgt 10.33%, erwartete Gewinnrendite 2.03%. PEG 0.14 (Peter Lynch unterbewertet ≤1,0). Die Graham-Zahl beträgt $19.41.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 85/100 mit 5/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | -12.3 | -0.28 | 6.45 | 192.80 | - |
| 2017 | -12.8 | -14.92 | 11.01 | 29.56 | - |
| 2018 | -8.3 | 0.47 | 4.27 | 9.15 | - |
| 2019 | -26.8 | 1.53 | 9.01 | 18.57 | - |
| 2020 | -29.9 | -2.52 | 13.41 | 19.04 | - |
| 2021 | -22.3 | 0.54 | 6.93 | 7.74 | - |
| 2022 | -11.9 | -0.43 | 6.43 | 4.98 | - |
| 2023 | -83.7 | 1.16 | 11.88 | 7.06 | - |
| 2024 | 13.4 | -0.03 | 4.15 | 3.17 | - |
| 2025 | 11.6 | 0.17 | 3.69 | 4.22 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $-2.34 | $17.33M | $-271.39M | -1565.9% |
| 2017 | $-2.36 | $124.9M | $-289.4M | -231.7% |
| 2018 | $-1.94 | $223.81M | $-245.19M | -109.6% |
| 2019 | $-1.60 | $339.08M | $-235.26M | -69.4% |
| 2020 | $-1.79 | $441.76M | $-281.58M | -63.7% |
| 2021 | $-1.05 | $484.15M | $-167.87M | -34.7% |
| 2022 | $-1.34 | $517.24M | $-215.98M | -41.8% |
| 2023 | $-0.37 | $726.44M | $-61.29M | -8.4% |
| 2024 | $1.36 | $957.8M | $226.45M | 23.6% |
| 2025 | $2.29 | $1.07B | $391M | 36.5% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $0.45 | $0.21 – $0.64 | $1.25B | $1.24B – $1.29B | 13 |
| 2027 | $0.85 | $0.01 – $1.65 | $1.39B | $1.27B – $1.48B | 11 |
| 2028 | $1.57 | $0.59 – $2.74 | $1.57B | $1.57B – $1.57B | 14 |
| 2029 | $1.91 | $1.77 – $1.99 | $1.67B | $1.58B – $1.73B | 8 |
| 2030 | $2.60 | $2.41 – $2.72 | $1.84B | $1.74B – $1.9B | 12 |
